Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3672 participants.
Also called NCT02666157
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,672 participants
- Registry
-
NCT02666157
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Unknown status
Technical summary
Registry record NCT02666157. Randomized; no masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Acronym
- DARING-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Dabigatran etexilate
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Apixaban
- Lead sponsor
- National Cheng-Kung University Hospital
- Collaborator
- Tainan Municipal Hospital
- Collaborator
- E-DA Hospital
- Collaborator
- National Cheng-Kung University Hospital Dou-Liou Branch
- Collaborator
- Ministry of Health and Welfare, Taiwan
Record details
- Record id
cardio:ct-nct02666157- Content hash
63b351f8a04c86fb1b0d40118b19f9126b1c8677b72362b9d9d4b1d0a534d13a